State Street Corp. Maintains Significant Passive Stake in Kura Oncology
Ticker: KURA · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds Kura Oncology stock, signaling institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Kura Oncology, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, but passive, investment in Kura Oncology. This matters to investors because State Street's large holding signals institutional confidence in Kura Oncology's future, potentially influencing other investors and providing a degree of stability to the stock.
Why It Matters
Large institutional ownership by entities like State Street can lend credibility to a company and its stock, as it suggests professional investors see long-term value. This can reassure current shareholders and attract new ones.
Risk Assessment
Risk Level: low — This filing is routine for large institutional investors and does not indicate any immediate risk or significant change in investment strategy.
Analyst Insight
Investors should view this filing as a routine update confirming State Street's continued, passive institutional ownership, which can be a positive signal of long-term confidence in Kura Oncology. It doesn't suggest any immediate buy or sell action but reinforces the company's institutional backing.
Key Numbers
- 50127T109 — CUSIP Number (identifies Kura Oncology, Inc. common stock)
- 04-2456637 — IRS Identification No. (identifies State Street Corporation)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Kura Oncology, Inc. (company) — the subject company whose common stock is being reported
- 0000093751-24-000076 (dollar_amount) — accession number for the filing
- December 31, 2023 (date) — the date of the event requiring the filing
Forward-Looking Statements
- State Street Corporation will maintain its passive investment in Kura Oncology, Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 12/31/2024
- Kura Oncology, Inc.'s stock will likely experience continued institutional interest due to its existing large holders. (Kura Oncology, Inc.) — medium confidence, target: 06/30/2024
FAQ
What is the purpose of this SC 13G/A filing?
This SC 13G/A filing by State Street Corporation is an amendment to a previous Schedule 13G, indicating their continued passive ownership of Kura Oncology, Inc. common stock as of December 31, 2023, under Rule 13D-1(B).
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is State Street Corporation, identified with IRS Identification No. 04-2456637, a large financial institution based in Boston, MA.
What company's stock is the subject of this filing?
The subject company is Kura Oncology, Inc., a pharmaceutical preparations company with CIK 0001422143, whose common stock is being reported.
What was the 'Date of Event Which Requires Filing of This Statement'?
The 'Date of Event Which Requires Filing of This Statement' was December 31, 2023, as stated on the cover page of the filing.
Under which SEC rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13D-1(B), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Kura Oncology, Inc. (KURA).